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AbstrAct
Alterations in genetic programs required for terminal myeloid differentiation 
and aberrant proliferation characterize acute myeloid leukemia (AML) cells. Here, 
we identify the host transcript of miR-223, linc-223, as a novel functional long non-
coding RNA (lncRNA) in AML. We show that from the primary nuclear transcript, the 
alternative production of miR-223 and linc-223 is finely regulated during monocytic 
differentiation. Moreover, linc-223 expression inhibits cell cycle progression and 
promotes monocytic differentiation of AML cells. We also demonstrate that endogenous 
linc-223 localizes in the cytoplasm and acts as a competing endogenous RNA for miR-
125-5p, an oncogenic microRNA in leukemia. In particular, we show that linc-223 
directly binds to miR-125-5p and that its knockdown increases the repressing activity 
of miR-125-5p resulting in the downregulation of its target interferon regulatory 
factor 4 (IRF4), which it was previously shown to inhibit the oncogenic activity of 
miR-125-5p in vivo. Furthermore, data from primary AML samples show significant 
downregulation of linc-223 in different AML subtypes. Therein, these findings indicate 
that the newly identified lncRNA linc-223 may have an important role in myeloid 
differentiation and leukemogenesis, at least in part, by cross-talking with IRF4 mRNA.
INtrODUctION
It is becoming increasingly apparent the relevance 
of non-coding RNAs (ncRNAs) in the genesis and 
progression of human cancer. At present, the majority 
of the studies on ncRNAs have mainly focused on 
microRNAs (miRNAs) expression and function. However, 
genome-wide studies have now shown that the mammalian 
genome is largely transcribed and that a relevant percentage 
of this transcription produces the heterogeneous class of 
long-ncRNAs (lncRNAs). Overall, the human genome 
originates more than ten thousands lncRNAs that, similarly 
to miRNAs, show tissue- and developmental stage- specific 
expression. The repertoire of lncRNAs involved in gene 
expression regulation is growing fast, as there is now 
evidence that lncRNAs participate in multiple networks 
controlling development and disease [1].
LncRNAs are emerging as key regulators of the 
development and function of the hematopoietic system [2]. 
Indeed, several lncRNAs are highly expressed in specific 
hematopoietic lineages and manipulation of their levels 
has been correlated with changes in cellular properties or 
differentiation [2]. However, many of them are still not 
functionally characterized. 
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Acute myeloid leukemia (AML) is characterized by 
genetic and epigenetic alterations in progenitor cells that 
produce complete or partial blockage at different stages 
of myeloid differentiation and uncontrolled proliferation 
[3]. Studying the functional interactions between genes 
that control the correct balance between cell proliferation 
and differentiation is critical to understand how their 
deregulated expression may contribute to leukemogenesis. 
In this context, lncRNAs might play an important role in 
the molecular pathogenesis of leukemia interfering with 
pathways essential for hematopoietic differentiation.
One of the first miRNAs to be functionally 
characterized in normal and pathological myelopoiesis 
is miR-223 [4–6]. MiR-223 is preferentially expressed in 
myeloid cells and is induced during retinoic acid (RA)-
mediated granulocytic differentiation of AML cells, at 
least in part, through the transcription factors C/EBPa and 
PU.1 [6–8]. MiR-223 is encoded in the third exon of what 
was previously defined a pri-miRNA transcript [7]. In this 
study we show that instead a spliced and polyadenylated 
non-coding RNA accumulates in the cytoplasm as an 
unprocessed species still containing the pre-miR-223 
sequence (here referred to as linc-223). Different studies 
showed functional association between miRNAs and their 
host genes, both for coding [9–11] and non-coding host 
transcripts [12, 13]. 
Here, we show that linc-223 is a cytoplasmatic 
RNA that is induced and stably accumulated during 
differentiation of AML cells and human cord blood CD34+ 
progenitor cells. Through modulation of linc-223 levels, 
we demonstrated that linc-223 expression inhibits cell 
proliferation and stimulates differentiation of AML cells. 
We showed that linc-223 acts, at least in part, by cross 
talking with the tumor suppressor IRF4 mRNA through 
competition for the binding of the oncogenic miR-125-5p. 
Furthermore, we found that linc-223 expression is 
downregulated in primary AML.
resUlts
linc-223 expression is associated with myeloid 
differentiation 
AML cell lines are widely used to study the block of 
differentiation in haematopoiesis and represent a suitable 
in vitro model for AML. By using the HL-60 cell line, 
which can differentiate either into granulocytes or 
monocytes by treatment with all-trans retinoic acid (ATRA) 
or 1,25-dihydroxy-vitamin D3 (VitD3), respectively, we 
found that the miR-223 host transcript [7] accumulates 
in the cytoplasm as a spliced RNA still containing the 
pre-miR-223 sequence (Figure 1A). This RNA, which 
is devoid of any coding potential (Supplementary Figure 
S1), has been named linc-223. Two splicing variants 
were found, which differ by exon 2 inclusion, and which 
are here referred to as linc-223-1 (1-2-3 exons) and 
linc-223-2 (1-3 exons). RT-PCR analysis indicated that 
linc-223 isoforms are polyadenylated and are localized 
in the cytoplasm (Figures 1B and 1C). Moreover, using 
primer sets specific for the two linc-223 isoforms, we 
showed by real-time PCR (qRT-PCR) that linc-223 was 
significantly induced during VitD3-mediated monocytic 
differentiation without a tight correlated induction of 
miR-223 expression (Figure 1D), suggesting different 
regulatory mechanisms. Linc-223 expression was also 
analyzed during monocytic differentiation of human 
cord blood CD34+ progenitor cells using a couple of 
oligonucleotides that recognises both isoforms (Figure 1E). 
Also in this case, linc-223 expression increased during 
differentiation without concomitant induction of miR-
223. High levels of linc-223 expression were also found 
in normal mature myeloid cells purified from peripheral 
blood compared to CD34+ progenitors (Figure 7). As 
previously reported [7, 14], we also detected increased 
linc-223 in ATRA-mediated granulocytic differentiation 
(Supplementary Figure S2). However, in this case it 
correlates with an increase of miR-223 levels [6, 7, 14]. 
Therein, these data indicate that from the primary nuclear 
transcript, the alternative production of miR-223 and linc-
223 is finely regulated during monocytic differentiation, 
suggesting that along this lineage linc-223 may play a 
specific function. 
linc-223 inhibits proliferation and stimulates 
monocytic differentiation of AMl cells
In order to assess the role of linc-223, we utilized 
shRNAs targeting linc-223 to down-regulate its expression 
levels. HL-60 cells were infected with two different 
lentiviral vectors expressing shRNAs against both linc-223 
isoforms (sh#1), linc-223-1 (sh#2) or scramble shRNA 
(sh-scr) and differentiation was evaluated by analyzing 
the immunophenotype and induction of specific molecular 
markers. Cells infected with either sh#1 and sh#2 
exhibited a significant decrease in linc-223 levels before 
and after VitD treatment (Figure 2A). Notably, a reduction 
of cells expressing the surface markers CD14 and 
CD11b, which are upregulated during myelomonocytic 
differentiation, was observed upon depletion of linc-
223 (Figures 2B and 2C). Moreover, in line with these 
results, reduced expression levels of M-CSFr, a marker of 
monocytic differentiation, was also detected (Figures 2D 
and Supplementary Figure S3). The shRNAs against 
linc-223 produced also a decrease in miR-223 expression 
levels (Figure 2A). To exclude the involvement of miR-
223 in monocytic differentiation following experiments 
were designed to specifically analyze linc-223 function.
HL-60 cells were stably transformed with a PiggyBac 
transposon system [15, 16] carrying Tet-inducible linc-
223 (EBP-linc223) and GFP (EBP-GFP), respectively. 
A linc-223 derivative deleted for the region required 
for Drosha cleavage was raised in order to specifically 
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obtain linc-223 expression without any miR-223 
contribution. Notably, the overexpression levels of linc-
223 after doxycyclin (dox) induction are comparable with 
those obtained by VitD treatment (compare Figures 1D 
and 3A). Moreover, miR-223 expression levels are not 
increased by EBP-linc223 (Figure 3A). In AML the 
terminal differentiation block is strictly related to aberrant 
proliferation (3). Thus, we analyzed the effect of linc-223 
on cellular proliferation and cell cycle. Ectopic expression 
of linc-223, but not of control GFP, greatly decreased the 
proliferation rate of HL-60 (Figure 3B). Moreover, cell 
cycle analysis showed that linc-223 expression increased 
the percentage of cells in G1 arrest and decreased the 
number of cells in S phase (Figures 3C and 3D). These 
data indicated that increased linc-223 levels are sufficient 
to inhibit proliferation of AML cells. We next analyzed 
the ability of VitD-treated HL-60 cells carrying the EBP-
linc223 or the control EBP-GFP expression cassettes to 
undergo monocytic differentiation. Strong increase of 
cells expressing the surface markers CD14 and CD11b 
(Figure 3E) and of the marker of monocytic differentiation 
M-CSFr (Figure 3F) was indeed observed upon induction 
of linc-223 and treatment with suboptimal doses of VitD 
(25 ng/ml). Altogether, these results indicate that linc-223 
Figure 1: linc-223 is a cytoplasmic lncrNA induced in monocytopoiesis. (A) Schematic representation of miR-223 primary 
transcripts (prim-miR-223), which can produce two lncRNA isoforms (linc-223-1 and linc-223-2) and miR-223. (b) RT-PCR for linc-223, 
unspliced pri-miR-223, HPRT mRNA and U6 snRNA from polyadenylated (pA+) and nonpolyadenylated (pA-) RNA purified from HL-60 
cells. (c). RT-PCR for linc-223, unspliced pri-miR-223 and HPRT mRNA from RNA isolated from cytoplasmic (CYT), nuclear (NUC), 
and chromatin (CHR) fractions of HL-60 cells. (D) qPCR analysis of miR-223 and linc-223 levels during VitD3-induced monocytic 
differentiation of HL-60 cell line. Values were normalized for U6 and HPRT mRNA expression, respectively. (e) qPCR analysis of miR-223, 
linc-223 and MCSFr levels during MCSF-induced monocytic differentiation of human CD34+ progenitor cells. Values were normalized for 
U6 (miR-223) and HPRT mRNA (linc-223 and MCSFr) expression. The histograms represent the means ± S.E.M. from triplicates.
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stimulated differentiation of AML cells while diminishing 
their proliferation rate.
linc-223 cross-talks with mir-125-5p and IrF4 
mrNA
It is known that lncRNAs may regulate gene 
expression by several mechanisms. An intriguing 
possibility is that linc-223 can enter circuitries of gene 
expression regulation by acting as competing endogenous 
RNAs (ceRNAs) [17]. Bioinformatics analysis for miRNA 
binding sites on linc-223 identified the oncogenic miR-
125-5p family (miR-125a, miR-125b1 and miR-125b2), 
which was shown to inhibit myeloid differentiation [18], 
and miR-223 itself as putative interactors. The miR-125-5p 
binding site is present in the third exon, which is in common 
to both isoforms, and it is conserved between human and 
mouse linc-223 despite a general low conservation between 
the linc-223 transcripts (Figure 4A). Thus, the linc-223 
sequence (RLuc-linc223) and mutant derivatives lacking 
the putative miR-125-5p (RLuc-linc223-Δ125) or miR-
223 (RLuc-linc223-Δ223) recognition sequences were 
cloned downstream of the luciferase gene and transfected 
together with either miR-125b or miR-223 coding 
plasmids (Figure 4B). The linc-223 sequence utilized in 
the reporter plasmids cannot produce miR-223 because is 
deleted for the region required for Drosha cleavage, but 
it still contained the region that can potentially base pair 
with miR-223. Luciferase expression of the RLuc-linc223 
construct was significantly reduced with respect to the 
control plasmid (pCTR) when miR-125b was expressed 
(Figure 4C). Notably, repression was abolished when the 
mutant miR-125-5p derivative RLuc-linc223-Δ125 was 
utilized. Conversely, no reduction of luciferase activity was 
Figure 2: lin-223 knockdown inhibits monocytic differentiation. (A) qPCR analysis of miR-223 and linc-223 levels upon 
knockdown of linc-223 by two different lentiviral constructs expressing shRNAs (sh#1 and sh#2). Lentivirus expressing a scramble shRNA 
(sh-scr) was utilized as control. Values were normalized for U6 (miR-223) and HPRT mRNA (linc-223) expression. The histograms represent 
the means ± S.E.M. from triplicates. (b) FACS analysis of CD11b and CD14 positive cells. Data presented are from one representative 
experiment. (c) The histogram represents the percentage of CD11b/CD14 positive cells before and after VitD3 treatment in HL-60 cell 
expressing scramble shRNA or shRNAs againsts linc-223 (see panel A). (D) qPCR analysis of MCSFr levels in HL-60 cell expressing 
scramble shRNA or shRNAs againsts linc-223. Values were normalized for HPRT mRNA expression. The histograms represent the means 
± S.E.M. from triplicates.
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observed in the presence of miR-223 (Figure 4C). Thus, 
these data indicate that linc-223 can be specifically targeted 
by miR-125-5p.
In order to further analyze the interaction between 
linc-223 and miR-125-5p, we performed a RNA pull down 
assay against the endogenous linc-223 in AML cells by 
using biotinylated DNA oligonucleotides complementary 
to linc-223 with HL-60 cytoplasmic extract. Biotinylated 
DNA oligonucleotides complementary to LacZ were 
utilized as control. Notably, miR-125-5p and Ago2 protein 
were specifically recovered with linc-223 from the fraction 
bound to the specific probes (Figures 4D, 4E and 4F). The 
absence of miR-223 from the pull-down confirmed the 
specificity of the interaction between miR-125-5p and 
linc-223 (Figure 4F). Altogether these data indicate that 
linc-223 can interact in vivo with miR-125-5p, associated 
with the Ago protein, and support the hypothesis that linc-
223 might act as a competing endogenous RNA (ceRNA) 
for miR-125-5p. 
MiR-125-5p is an oncogenic miRNA family that is 
able to impair myeloid differentiation and to transform 
myeloid cells [18, 19]. Among the validated miR-125-
5p target mRNAs, we focused on the transcription factor 
IRF4 (interferon regulatory factor 4). Indeed, it has been 
shown that miR-125-5p induces tumorigenesis in myeloid 
cells through the repression of IRF4 mRNA [20] and, 
above all, that the expression of a IRF4 derivative without 
miR-125-5p binding sites rescues miR-125-5p induced 
Figure 3: ectopic expression of linc-223 inhibits proliferation and stimulates differentiation. (A) Analysis of miR-223 
and linc-223 levels in HL-60 cells containing linc-223 expression cassette (EBP-linc223) before (-dox) and after induction (+dox) with 
Doxycycline. Level of expression was measured by qRT-PCR relative to U6 snRNA for miR-223 and HPRT mRNA for linc-223. Error bars 
represent S.E.M. from three independent experiments. (b) Growth curve of HL-60 cells containing GFP (EBP-GFP) and linc-223 (EBP-
linc223) expression cassette, respectively, before (-dox) and after induction (+dox) with Doxycycline. (c) Cell cycle distribution of cells 
with EBP-GFP and EBP-linc223 expression cassette. (D) Representative cell cycle analysis of (C). (e) qPCR analysis of CD11b and CD14 
upon VitD3 treatment in HL-60 cells expressing GFP or linc223. (F) qPCR analysis of MCSFr levels in HL-60 cells expressing GFP or 
linc-223. Error bars represent S.E.M. from three independent experiments.
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myeloid leukemia [20]. IRF4 protein levels matches 
that ones of linc-223 during monocytic differentiation 
showing an increase between 72 hrs and 96 hrs of VitD 
treatment (Figure 5A). Furthermore, IRF4 mRNA and 
miR-125-5p levels did not change significantly during 
this period of time (Figure 5B). To better understand the 
regulation of IRF4 expression we performed polysome 
profile by sucrose gradient analysis of HL-60 cells, either 
untreated (CTR) or treated with VitD for 72 hours (VitD). 
Interestingly, the increase of IRF4 protein levels upon VitD 
treatment was accompanied by a shift of IRF4 mRNAs 
toward the polysomal fraction of the gradient (Figure 5C), 
despite a general decrease of translation. These data are 
consistent with a reduction of miRNA repressing activity 
on IRF4 mRNA.
In line with a decoy mechanism, the predicted ΔG 
of binding of miR-125-5p with linc-223 is lower than 
that with IRF4 (Figure 6A). Absolute quantification in 
Figure 4: linc-223 interacts with mir-125b. (A) Base-pairing between miR-125-5p family members and linc-223 in human and 
mouse. (b) Schematic representation of linc-223 ΔDrosha constructs wild type (RLuc-Linc223) and mutant derivatives devoid of miR-223 
(RLuc-linc223-Δ223) or miR-125b (RLuc-linc223-Δ125) binding sites used in the luciferase assays. (c) HL-60 cells were electroporated 
with linc223 reporters together with plasmids expressing miR-125b-5p (pMiR-125b) or miR-223 (pmiR-223) or with a control vector 
(pCTR). FF luciferase values were normalized to RL luciferase reading. Data, derived from five independent experiments, are shown 
with respect to RLuc control vector set to a value of 1. Data are shown as mean ± SD. Expression differences were statistically analyzed; 
p < 0.05  =  * (D) Biotinylated antisense DNA oligonucleotides complementary to linc-223 (L223) were incubated with cytoplasmic extracts 
of HL-60 cells. DNA oligonucleotides complementary to LacZ (LacZ) and beads only (BO) were utilized as controls. RNA pull-down was 
performed with streptavidin-linked beads. The recovered linc-223 assessed by RT-PCR from input extract and pull-down with L223, lacZ 
and BO are shown. (e) Western blot analysis of Ago2 and HPRT from input, L223, LacZ and BO. (F) The histograms show the recovery 
of miR-125b-5p and miR-223 indicated as percentage of input in fraction bound to L223, lacZ and BO. Error bars represent S.E.M from 
triplicates. Input represents 10% of the extract used for the pull-down. 
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HL-60 indicated that miR-125-5p and linc-223 show 
comparable expression levels while linc-223 copies 
are about twenty times more then IRF4 (Supplemental 
Figure S4). Moreover, upon VitD treatment the expression 
of linc-223 is about 200 times that one of IRF4 while miR-
125-5p levels are not changed significantly (Figures 5B 
and 6B). Therein, we analyzed the levels of IRF4 protein 
upon knock-down of linc-223 during VitD3-mediated 
monocytic differentiation. In agreement with our ceRNA 
hypothesis, we observed a significant reduction of IRF4 
with lower linc-223 levels while miR-125b levels were 
not affected (Figure 6C). To further demonstrate the cross-
talking between linc-223 and IRF-4, we transfected K562 
cells with a luciferase reporter containing IRF4 3’-UTR 
(RLuc-IRF4-3’-UTR) in combination with miR-125b 
alone or together with wild-type linc-223 or a mutant 
derivative lacking the putative miR-125-5p binding 
site (linc223-Δ125), respectively. As expected, miR-
125b decreased the expression of RLuc-IRF4-3’-UTR 
(Figure 6D). The concomitant expression of linc-223 
partially recovered the IRF4 repression while the 
expression of linc223-Δ125 showed a minor but still 
significant effect. These data indicate the existence of 
a specific crosstalk between linc-223 and IRF4 mRNA 
through competition for miR-125-5p binding.
linc-223 is downregulated in AMl 
We evaluated linc-223 expression in gene expression 
arrays of different AML subtypes (Supplementary 
Table S1), mature polymorphonucleated cells (PMNs) 
and CD34+ progenitor cells. We found significant 
downregulation of linc-223 expression compared to PMNs 
in AML of the M0, M1 and M3 subtypes (Figure 7A). 
The lowest expression of linc-223 was detected in AML 
of the M3 subtype. Notably, although miR-125-5p is able 
to induce leukemia in mouse when overexpressed in the 
hematopoietic system [18, 21], in primary human AML 
it was found upregulated only in the M3 FAB subtype 
[22, 23]. Thus, we analyzed the correlation of miR-125-
5p family members (miR-125a, miR-125b1 and miR-
Figure 5: Analysis of IrF4 expression. (A) Western blot analysis of IRF4 and HPRT protein levels during VitD3-induced monocytic 
differentiation of HL-60 cells. (b) qPCR analysis of IRF4 mRNA and miR-125b-5p levels during VitD3-induced monocytic differentiation 
of HL-60 cell line. Values were normalized for HPRT mRNA. (c) Cytoplasmic extracts from HL-60 cells, either untreated (CTR) or treated 
with VitD for 72 hours (VitD), were loaded on 15–50% sucrose gradients and fractions measured by absorbance at 253 nm. Fraction density 
decreases from left to right; the panels show one representative profile out of three independent biological replicates. Pooled fractions of 
RNA associated with polysomes, monosome and free RNA were analyzed by qRT-PCR and represented as percentage of RNA level in each 
of the fractions. Profiles are shown for IRF4 mRNA and GAPDH mRNAs. 
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125b2), IRF4 and linc-223 in AML M3 with respect to all 
others AML subtypes. As reported, we observed a specific 
upregulation of miR-125b in AML-M3. Interestingly, an 
inverse correlation between the expressions of miR-125b 
and linc-223 was observed while IRF4 expression was 
constant (Figure 7B). Therein, these data indicate that 
the linc-223 downregulation observed in AML M3 might 
contribute to the oncogenic activity of miR-125-5p by 
increasing its repressing activity on IRF4 mRNA.
DIscUssION
Several lncRNAs have been shown to be involved 
in normal and malignant hematopoiesis [2]. However, only 
few lncRNAs have been functionally characterized. In recent 
years, it has been discovered that lncRNAs can prevent 
miRNA repressive activity on their target mRNAs through 
binding to specific miRNAs [12]. Thus, acting as competing 
endogenous RNAs (ceRNAs). Several studies showed that 
Figure 6: linc-223 cross-talks with IrF4. (A) Base-pairing between miR-125-5p and linc-223, and miR-125-5p and IRF4 3’-UTR, 
ΔG values were obtained from miRanda (http://www.microrna.org). (b) Left panel: absolute number of miR-125-5p, linc-223 and IRF4 
molecules for cells (n). Right panel: ratio between linc-223 and IRF-4 mRNA in HL-60, either untreated (CTR) or treated with VitD for 
72 hours (VitD), measured by qPCR. Values were normalized for HPRT mRNA expression. (c) Left panel: western blot analysis of IRF4 
and HPRT protein levels in HL-60 cells expressing scramble shRNA (sh-scr) or shRNAs against linc-223 (sh#1 and sh#2); right panel: 
qPCR analysis of miR-125b levels relative to U6 snRNA in HL-60 cells expressing scramble sh-scr or sh#1 and sh#2. (D) K562 cells 
were transfected with IRF4-3’UTR reporter together with plasmids expressing miR-125b-5p, RLuc-linc223 or RLuc-linc223-Δ125. FF 
luciferase values were normalized to RL luciferase reading. Error bars represent S.E.M from triplicates. Expression differences were 
statistically analyzed; p < 0.05  =  *.
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the disruption of the equilibrium between ceRNAs and 
miRNAs can be critical in many biological processes and 
can contribute to cancer development [17, 24–6]. In this 
manuscript, we show that the host non-coding transcript 
of miR-223, linc-223, is a functional lncRNA that controls 
proliferation and differentiation of AML cells, at least in part, 
by binding miR-125-5p and competing for its repressing 
activity on IRF4. MiR-125-5p has been previously 
associated with leukemogenesis [27]. In particular, MiR-
125b was found significantly increased in primary AML cells 
of the M3 FAB subtype [22, 23] where linc-223 was instead 
found at low expression levels. MiR-125b is able to induce 
myeloid leukemia when overexpressed in the hematopoietic 
compartment in mouse [18, 21]. Notably, the oncogenic 
activity of miR-125b in vivo can be rescued by the expression 
of its target IRF4 devoid of miR-125b binding sites [20]. 
Therein, indicating IRF4 as a crucial miR-125-5p target in 
myeloid leukemia. Here, we show that decrease in linc-223 
levels produce a downregulation of IRF4 expression, thus 
pointing to linc-223 as a novel oncosuppressor in AML. 
Figure 7: Analysis of linc-223 expression in AMl patients and normal hematopoietic cells. (A) Quantitative expression 
analysis of linc-223 in primary leukemia cells derived from AML patients from TCGA, normal CD34+ progenitors and mature 
polymorphonucleated cells (PMNs). The different FAB subtypes are indicated in the graph. (b) Quantitative expression analysis of miR-
125-5p family members, linc-223 and IRF4 in AML of the M3 subtype (M3) compared to all the other subtypes (all other). Expression 
differences were statistically analyzed; p < 0.01 *; p < 0.001**
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As linc-223 and IRF4 might share binding sites for 
other different microRNAs, we can speculate that their 
cross-talking might be much more complex than what has 
been described in this study. Furthermore, the regulative 
network described here might represent a small part of a 
more elaborated cross-talk, which might include many 
other components (such us pseudogenes, circRNAs and 
other lncRNAs).
Whether linc-223 affects miR-125-5p function 
in vivo requires to be further investigated and represents a 
relevant topic to be addressed in the future.
Interestingly, we observed different regulation 
of miR-223 and linc-223 expression during monocytic 
differentiation of both normal hematopoietic progenitors 
and AML cells. MiR-223 transcription is predominantly 
regulated by a conserved promoter in front of the pri-
miR-223/linc-223 transcription start site [7, 28] and, to 
a lesser extent, by a non-conserved intronic promoter 
upstream to the pre-miRNA sequence [6, 28, 14]. 
Previous data showed that both promoters determine the 
high expression levels of mature miR-223 in granulocytic 
cells. On the other hand, pri-miR-223/linc-223 showed 
different expression pattern relative to miR-223 during 
monocytic differentiation. Moreover, while miR-223 
expression promotes granulocytic differentiation it impairs 
monocytopoieis of CD34+ [14]. Therefore, the balance 
between linc-223 and miR-223 expression may be relevant 
for the lineage-specific differentiation/maturation choice 
of myeloid progenitors during hematopoiesis. Our data 
suggest that during monocytic differentiation a specific 
post-transcriptional mechanism could control the relative 
production of linc-223 versus miR-223, possibly at the 
level of microprocessor activity, similarly to what already 
shown for other miRNA-containing lncRNAs [29, 30]. 
Further studies are needed to unravel these mechanisms 
and to determine their implications in AML. 
MAterIAls AND MetHODs
cell cultures and reagents
HL-60 and K562 cell lines were maintained in 
RPMI 1640 medium supplemented with 1 × Penicillin/
Streptomicin solution, 1 × L-glutamine and 10% Fetal 
Bovine Serum. All utilized cell lines were tested for 
mycoplasma contamination. All-trans-retinoic acid (ATRA) 
and 1,25-Dihydroxyvitamin D3 (VitD) were purchased 
from Sigma and utilized at a concentration of 1 μM and 
250 ng/ml, respectively, unless differently specified. 
Doxycycline (Dox) was purchased from Sigma and utilized 
at a concentration of 200 ng/ml, unless differently specified. 
rNA extraction and real-time qrt-Pcr analysis
Total RNA was extracted using the Quick 
RNA miniprep kit (Zymo) according to manufacturer 
instructions. For mRNA analysis, reverse transcription 
to cDNA was performed with the SuperScript VILO 
cDNA Synthesis Kit (Life Technologies) according to the 
manufacturer instructions. Quantitative real-time PCR 
was performed on an Applied Biosystems 7500 Fast Real 
Time PCR System. Reactions were performed in triplicate 
using the SYBR green dye detection system and analyzed 
using 7500 Software v2.0.6 (Applied Biosystems). 
Relative expression levels of targets were determined 
using the comparative 2∆∆Ct method. Hypoxanthine-
guanine phosphoribosyltransferase (HPRT) mRNA was 
utilized as a reference. MicroRNA analysis by real-time 
PCR was performed using miScript System (QIAGEN) 
for hsa-miR-223 and hsa-miR-125b, and delta-delta Ct 
values were normalized with those obtained from the 
amplification of the endogenous U6 snRNA (QIAGEN). 
All reactions were performed in triplicate. Expression 
differences were statistically analyzed using a Student’s 
t-test.
Nuclear/cytoplasmic fractionation was carried 
out by using the NE-Per Kit (Thermo Scientific-Pierce) 
according to the manufacturer’s specifications. PolyA+ 
RNA fraction was obtained using Oligotex mRNA 
Mini Kit (Qiagen) according to the manufacturer’s 
specifications. RT-PCRs were performed by amplifying 
cDNA with MyTaq™ HS Red DNA Polymerase (Bioline) 
and specific oligonucleotides listed below. 
Relative quantification of miR-125-5p, linc-223 
and IRF4 mRNA was performed by real-time PCR using 
miScript II reverse transcription system (QIAGEN), 
and normalized with the endogenous HPRT. Absolute 
quantification of miR-125-5p, linc-223 and IRF4 was 
measured through qRT-PCR calibrating with an internal 
standard curve of synthetic constructs, as previously 
described [31].
linc-223 knockdown and overexpression
Linc-223 knockdown was obtained by Mission 
Lentiviral shRNA clones (Sigma-Aldrich, USA). 
Mission Lentiviral Non-Targeting shRNA clone SHC002 
(Sigma-Aldrich, USA) was utilized as control. Lentiviral 
particles were prepared according to the manufacturer’s 
specifications. Infection of AML cell lines was performed 
as previously described [32]. Targeting sequences 
are CTGTCCTAGAGAAACTTTATA for Sh#1 and 
CAGCCCAGTACTTTAGTTACA for Sh#2.
For linc-223 ectopic expression, stable and inducible 
HL-60 cell lines were produced as previously described 
[15, 16]. Briefly, linc-223 cDNA was amplified from 
HL-60 cells and subcloned in the enhanced PiggyBac 
(ePB) vector ePB-PURO using the oligonucleotides 
Linc-223-BamHI-FW and Linc-223-NotI-REV. Deletion 
of the Drosha cleavage site was obtains by inverse 
PCR with oligonucleotides Linc-223-mut.223-FW and 
Linc-223-mut.223-REV generating the EBP-linc223 
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plasmid. GFP sequence for control EBP was amplified 
from a commercial EBP plasmid contains a TET-on 
system for inducible transgene expression. Helper and 
transposon plasmids were electroporated in HL-60 with 
the Neon Transfection System (Invitrogen) according 
to manufacturer instruction. Selection with 1 μg/mL of 
puromycin (SIGMA) was initiated 2 days after transfection 
and maintained until resistant colonies became visible.
rNA pull-down
HL-60 cells were treated with VitD for 72 hours and 
30 × 106 cells were collected and washed with ice cold 
PBS and resuspended in Buffer A (20 mM Tris pH 7.4, 10 
mM NaCl, 3 mM MgCl, 0.1% NP40, 0.2 mM EDTA, 10% 
glycerol). 800 μg of supernatant (cytoplasmic extract) were 
incubated with tRNA-saturated magnetic beads (Streptavidin 
MagneSphere Paramagnetic Particles, Promega) and ten 
biotinylated DNA probes in IP-Buffer (20 mM Hepes 
KOH pH 7.4, 150 mM KCl, 2 mM MgCl2, 0.01% Triton 
X-100, 5% glycerol, 1 mM DTT) for 1 hrs at R.T. Beads 
were washed four times with IP-Buffer and resuspended in 
1 mL of Trizol and Protein loading dye for RNA and protein 
analysis, respectively. Protein levels were analyzed by 
western blot as previously described (Hughes et al., 2015). 
Antibodies utilized were against Ago2 (ab32381, Abcam) 
and HPRT (FL-218, Santacruz Biotechnology).
luciferase assay
Linc-223 was amplified with oligonucleotides 
Linc-223-XhoI-FW and Linc-223-NotI-REV then cloned 
in the psicheck2 plasmid (Promega), downstream from 
the Renilla luciferase (RLuc) gene. The same plasmid 
also contains the Firefly luciferase (FLuc) to normalize 
transfection efficiency. The mutant derivative lacking 
the miR-125 binding site was obtained by inverse PCR 
with the oligonucleotides Linc-223-mut.125b-FW and 
Linc-223-mut.125b-REV. The mutant derivative lacking 
the miR-223 binding site was obtained by inverse PCR 
with the oligonucleotides Linc-223-mut.223-FW and 
Linc-223-mut.223-REV. IRF4 3’-UTR was amplified 
with oligonucleotides IRF4-XhoI-FW and IRF4-NotI-
REV then cloned in the psicheck2 plasmid (Promega), 
downstream from the Renilla luciferase (RLuc) gene. 
RLuc and FLuc activities were measured by Dual Glo 
luciferase assay (Promega). Expression differences were 
statistically analyzed using a Student’s t-test.
cell proliferation and differentiation
For cell cycle analysis, 2 × 105 cells were resuspended 
in 50% FCS, fixed in 70% ethanol for 24 hours, incubated 
with 50 Ag/mL propidium iodide (Sigma-Aldrich) and 
50 units/mL DNase free RNase A (Sigma-Aldrich), and 
analyzed after 3 hours (10,000 events) using an Epics XL 
Cytometer (Beckman Coulter). Differentiation was assessed 
by NBT dye reduction assay and direct immunofluorescence 
staining of cells using an Allophycocyanin (APC) anti-
human CD11b (Becton Dickinson), APC anti-human 
PerCP-Cy5.5 anti-human CD14 (Becton Dickinson) and 
PE-IgG1 isotype control (eBiosciences) as previously 
described (Salvatori et al., 2012). A minimum of 10,000 
events was collected for each sample with flow cytometer 
(CyAN ADP DAKO) by using Summit 4.3 software for 
data acquisition and analysis.
Polysome profiling
Cytoplasm fractionations on sucrose gradients 
were performed as follows: 20 × 106 cells were lysed 
with 500 ml of lysis buffer (10 mM Tris pH 7.5, 100 mM 
NaCl, 10 mM MgCl2, 0.5% Triton X-100, and 0.5% 
sodium deoxycholate) supplemented with 100 mg/ml 
cycloheximide, 1X PIC (Complete, EDTA free, Roche) 
and 1X RNase guard (Thermo Scientific). The lysates 
were centrifuged for 10 min at 13000 rpm at 4°C. 
The supernatants were collected and centrifuged on 
15%–45% sucrose gradient at 38000 rpm with a SW41 
rotor (Beckman) for 1 h 30 min at 4°C. Fractions 
were collected with a Bio-logic LP (Biorad), 10 mg of 
glycogen and 100 μg of Proteinase K (Roche) was added 
to each fraction. Samples were left 1 h at 37°C and RNA 
was purified by PCA extraction and precipitated with 
isopropanol.
Data analysis
Data were downloaded from GEO DataSets 
GSE16020 (PMN_control_Rneasy 1–7), GSE19429 
(CD34+ Healthy control 1–17) and from the TCGA 
Research Network (AML samples). Information of TCGA 
AML patients are listed in Supplementary Table S1. 
All data were derived from microarray experiments 
performed with GeneChip® Human Genome U133 
Plus 2.0 Array (GPL570). We used the software 
package DNA-Chip Analyzer (dChip) for probe-level 
(e.g. Affymetrix platform) and high-level analysis of 
gene expression microarrays and SNP microarrays to 
normalize CEL files. The normalization was performed 
using an array with median overall intensity chosen as the 
baseline array against which other arrays are normalized 
at probe intensity level. In this way the brightness of the 
arrays was adjusted to comparable level. We utilized 
the same software to compute model-based expression 
values for each arrays. The expression values of interest 
were than analyzed. P value was calculated using two-
tailed Mann-Whitney U-test.
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Oligonucleotides
Oligonucleotides used in this study:
qRT-PCR:
Linc-223 FW GAAAGCCCAATTCCATCTG
Linc-223 REV AGTGGAGTGGTGCCTTGGT
MCSFR FW TCCAAAACACGGGGACCTATC
MCSFR REV TCCTCGAACACGACCACCT
IRF4-FW CAGTTCAGCGGTTGAGGAGA
IRF4-REV AATGCAAAGCCACCCTTCCT
CD11b-FW CCTGGTGTTCTTGGTGCCC
CD11b-REV TCCTTGGTGTGGCACGTACTC
CD14-FW AAAGGACTGCCAGCCAAGCT
CD14-REV GATTCCCGTCCAGTGTCAGGT
RT-PCR:
Linc-223 FW CAAGGCACCACTCCACTGAC
Linc-223 REV ATATCCCATCTGCCCTGGC
Pri-miR-223 FW TCAGGATCTCTCTTCTGGTTAGG
Pri-miR-223 REV GATCTTGCTCAAAGGACCAAC
Linc-223-2 FW ACTGACAGGGTCACATCT
Linc-223-2 REV GACAAACTGACACTCTACCAC
HPRT FW GCCATCACATTGTAGCCCTCTG
HPRT REV TTTATGTCCCCTGTTGACTGGTC
Cloning:
Linc-223 BamHI FW CGCGGATCCAGAAAGCCCAATTCCATC
Linc-223 NotI REV AAAAGCGGCCGCAACTCCTCAGTGCATATATTTATT
Linc-223-mut.223 FW AAGTGCGGCACATGCTTACCA
Linc-223-mut.223 REV CTCTACCACATGGAGTGTCCAA
Linc-223-mut.125b FW AAATACAGCCCTGGGCTGTG
Linc-223-mut.125b REV ATGCCACACTTTTCCCCTGG
Linc-223 XhoI FW CCGCTCGAGAGAAAGCCCAATTCCATCTGGCCC
IRF4 XhoI FW CCGCTCGAGAAAATGTCAAGATGAGTGGTT
IRF4 NotI REV AAAAGCGGCCGCTAACAAATTTTTAAAAGTTTTTAT
Linc-223 pull down:
Oligo#1 CATTCGTCATATCCCATCTG
Oligo#2 GGTGTCCTCAGATATAATGC
Oligo#3 GAGAATGCTGATGTCCTAGA
Oligo#4 CTTTAGCTGGTCCAGGAAAT
Oligo#5 ATCCTTCATGCTGGCTACTA
Oligo#6 AACTTGTGAGAACTTGGTGC
Oligo#7 TCATGGTGTGTGTAGACACA
Oligo#8 CAGATAAGCCATTAGGCTTG
Oligo#9 GGTGCTATTAGACAGTAGGA
Oligo#10 GACACTGTTTCTCAGGAAGA
LacZ pull down:
Oligo#1 CCAGTGAATCCGTAATCA
Oligo#2 GTAGCCAGCTTTCATCAACA
Oligo#3 AATGTGAGCGAGTAACAACC
Oligo#4 AATAATTCGCGTCTGGCCTT
Oligo#5 ATTAAGTTGGGTAACGCCAG
Oligo#6 AATTCAGACGGCAAACGACT
Oligo#7 AATAATTCGCGTCTGGCCTT
Oligo#8 AGATGAAACGCCGAGTTAAC
Oligo#9 AATTCAGACGGCAAACGCT
Oligo#10 TTTCTCCGGCGCGTAAAAAT
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